New chief executive for the International Diabetes Federation
pharmafile | November 11, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | diabetes, petra wilson
The International Diabetes Federation (IDF) has appointed Dr Petra Wilson as its chief executive.
Wilson joins IDF from Cisco, where she was senior director of the European Health and Care Business Solutions team. At Cisco she worked with the WHO, the European Commission, national and regional governments, and healthcare organisations on healthcare policies.
Wilson has previously been director of the European Health Management Association, and a scientific officer for the European Commission (EC) where she led the work on the European eHealth Action Plan.
Before her role at the EC she was a senior lecturer in law at the University of Nottingham, where she taught in both the law and medical schools.
Wilson will continue her roles as honorary reader at the Centre for Health Informatics and Multiprofessional Education at University College London, and as a non-executive director of the Digital Health Institute in Scotland.
Sir Michael Hirst president of the IDF, said: “Petra brings many strengths to IDF and the world wide community of people with diabetes, researchers and practitioners. This will be a challenging role and we believe that Petra has much to contribute. We are very pleased that she has accepted the position”.
Wilson added: “I am delighted to be taking up this challenging post. Diabetes is one of the most pressing health challenges globally, which demands that people, organisations, communities and nations work together to create a better future for those affected by the disease. IDF has a deservedly high reputation as a forthright advocate for people with diabetes, and I look forward to being part of such a dynamic global movement.”.
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
